Healthcare Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare
SECTOR
Life Sciences

RELEASE DATE
12-Aug-2021
REGION
North America
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
MG1B-01-00-00-00
SKU
HC03437-GL-MR_25633
Yes
SHARE

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021
Published on: 12-Aug-2021 | SKU: HC03437-GL-MR_25633

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPT’s debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving accuracy and positive predictive value. Frost & Sullivan forecasts a quadruple increase in penetration for average-risk pregnancies in 2021. Scalable, automated in-lab workflow solutions and remote patient monitoring in pregnancy will effectively address the incoming volume and improve overall test economics. A significant proportion of consolidation is focused on the distribution and marketing of NIPTs to expand access and coverage, followed by product development and commercialization agreements. Frost & Sullivan envisages the trend in consolidation to increase in the coming age of distributable kits, offering new solutions to drive the expansion of testing to all autosomes and microdeletions. As the clinical application becomes widespread, major leaps forward are on the horizon, including sequencing-free optics-based technology and approaches that analyze whole-fetal cells instead of cfDNA. Expanded clinical application of NIPT will accelerate technological developments in the field, making the sector a viable market.

Author: Amartya Bose

Strategic Imperative

Strategic Imperative (continued)

Strategic Imperative (continued)

Growth Environment

Growth Environment (continued)

Growth Environment (continued)

Frost Radar™: Non-Invasive Prenatal Testing Market, Global, 2021

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

Natera, Inc.

Illumina, Inc.

LabCorp

BGI Genomics Co., Ltd

Roche

Yourgene Health Plc.

Quest Diagnostics

Eurofins Scientific (GeneTech)

PerkinElmer, Inc.

Cradle Genomics

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025   |   Global   |   Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

17 Dec 2024   |   Global   |   Market Research

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

12 Dec 2024   |   Global   |   Market Outlook

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

05 Dec 2024   |   Global   |   Frost Radar

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...

27 Nov 2024   |   Global   |   Market Research

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving accuracy and positive predictive value. Frost & Sullivan forecasts a quadruple increase in penetration for average-risk pregnancies in 2021. Scalable, automated in-lab workflow solutions and remote patient monitoring in pregnancy will effectively address the incoming volume and improve overall test economics. A significant proportion of consolidation is focused on the distribution and marketing of NIPTs to expand access and coverage, followed by product development and commercialization agreements. Frost & Sullivan envisages the trend in consolidation to increase in the coming age of distributable kits, offering new solutions to drive the expansion of testing to all autosomes and microdeletions. As the clinical application becomes widespread, major leaps forward are on the horizon, including sequencing-free optics-based technology and approaches that analyze whole-fetal cells instead of cfDNA. Expanded clinical application of NIPT will accelerate technological developments in the field, making the sector a viable market. Author: Amartya Bose
More Information
Deliverable Type Frost Radar
No Index No
Podcast No
Author Amartya Bose
Industries Healthcare
WIP Number MG1B-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9562-B1,9573-B1,99C6-B1,9627-B1

Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03437-GL-MR_25633